DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis. SeylanMED is committed to the development of a topical Akt inhibitor as a first in class treatment for Seborrheic Keratosis (SK). Our lead drug candidate, SM-020, is the first molecularly-targeted approach for the treatment of SK. SeylanMED is funded by angel investors including board-certified dermatologists.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.